A citation-based method for searching scientific literature

John B Buse, Richard M Bergenstal, Leonard C Glass, Cory R Heilmann, Michelle S Lewis, Anita Y M Kwan, Byron J Hoogwerf, Julio Rosenstock. Ann Intern Med 2011
Times Cited: 389



John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
Times Cited: 1040




List of shared articles



Times cited

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Michael A Nauck, Daniel R Quast, Jakob Wefers, Juris J Meier. Mol Metab 2021
34



Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Raffaella Gentilella, Valeria Pechtner, Antonella Corcos, Agostino Consoli. Diabetes Metab Res Rev 2019
80

Effects of liraglutide addition to multiple diabetes regimens on weight and risk of hypoglycemia for a cohort with type 2 diabetes followed in primary care clinics in Saudi Arabia.
Yasser A Albarkah, Ayla M Tourkmani, Abdulaziz M Bin Rsheed, Turki J Al Harbi, Yasser A Ebeid, Reuof A Bushnag. J Family Med Prim Care 2019
3

Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
Vjera Ninčević, Tea Omanović Kolarić, Hrvoje Roguljić, Tomislav Kizivat, Martina Smolić, Ines Bilić Ćurčić. Int J Mol Sci 2019
18

Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies.
Guillermo E Umpierrez, Timothy S Bailey, Danielle Carcia, Charles Shaefer, Jay H Shubrook, Neil Skolnik. J Diabetes 2018
8

Pharmacotherapy of type 2 diabetes: An update.
Jagriti Upadhyay, Stergios A Polyzos, Nikolaos Perakakis, Bindiya Thakkar, Stavroula A Paschou, Niki Katsiki, Patricia Underwood, Kyung-Hee Park, Jochen Seufert, Eun Seok Kang,[...]. Metabolism 2018
82

Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.
Greer Waldrop, Jixin Zhong, Matthew Peters, Aditya Goud, Yin-Hsiu Chen, Stephen N Davis, Bhramar Mukherjee, Sanjay Rajagopalan. J Diabetes Complications 2018
15



A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin.
Denis Raccah, Engels Chou, Stephen Colagiuri, Zsolt Gaàl, Fernando Lavalle, Ashot Mkrtumyan, Elena Nikonova, Nikolaos Tentolouris, Josep Vidal, Melanie Davies. Diabetes Metab Res Rev 2017
21


Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Inka Miñambres, Antonio Pérez. Diabetol Metab Syndr 2017
12




Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.
Kelvin Lingjet Tran, Young In Park, Shalin Pandya, Navin John Muliyil, Brandon David Jensen, Kovin Huynh, Quang T Nguyen. Am Health Drug Benefits 2017
47


THE EFFECT OF EXENATIDE THERAPY IN PREVIOUSLY INSULIN-TREATED TYPE 2 DIABETIC PATIENTS.
H Y Yaşar, B Ozturk Ceyhan, B O Pamuk, M Demirpence, O Ertugrul, D Ertugrul. Acta Endocrinol (Buchar) 2017
0




Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
L Østergaard, Christian S Frandsen, S Madsbad. Expert Rev Clin Pharmacol 2016
17



GLP-1 Agonists and Blood Pressure: A Review of the Evidence.
Aditya Goud, Jixin Zhong, Matthew Peters, Robert D Brook, Sanjay Rajagopalan. Curr Hypertens Rep 2016
37